TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    AMZN (-3%)    SPY (-1.93%)    SQ (-4.39%)    TAC (-1.18%)    TARO (-0.12%)    TSLA (-3.47%)    UNIT (-3.04%)    UTX (-1.37%)    VXXB (11.47%)    WYNN (-3.5%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    BA (-2.83%)    BAC (-4.16%)    BIIB (-4.49%)    BPTH (18.94%)    CFMS (-1.65%)    CHKP (-0.58%)    CLRB (-6.1%)    CSIQ (-2.75%)    CVRS (2.72%)    CZZ (-7.45%)    DIS (-0.4%)

 EIDX - Eidos Therapeutics

$21.32 [-0.61][-2.79%]

Next Earnings

3/29/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $29.00
Low $28.00
Average $28.50
Current $21.32

CompanyAnalyst NamePT ActionActionRatingTargetDate
BMO CapitalAnnouncesInitiates Coverage OnStrong Buy$28.0002/22/19
JP MorganAnnouncesDowngradesHold$29.0001/23/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $EIDX

No traders tracking are currently recommending this stock

TRENDING ARTICLES



Can This Biotech Puppy Run With the Big Dogs?

03/04/19
If you ve never heard of Eidos Therapeutics NASDAQ EIDX during its eight month history as a public company try not to beat yourself up about it On an average week in 2018 at least one new biotech stock began trading on U S exchanges Staying on top of every new drugmaker